Biosyntech Performance
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and Biosyntech are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Biosyntech has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong basic indicators, Biosyntech is not utilizing all of its potentials. The recent stock price confusion, may contribute to short-horizon losses for the traders. ...more
Biosyntech |
Biosyntech Relative Risk vs. Return Landscape
If you would invest (100.00) in Biosyntech on September 30, 2025 and sell it today you would earn a total of 100.00 from holding Biosyntech or generate -100.0% return on investment over 90 days. Biosyntech is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Biosyntech, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Biosyntech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biosyntech's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Biosyntech, and traders can use it to determine the average amount a Biosyntech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| BSYI |
Based on monthly moving average Biosyntech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biosyntech by adding Biosyntech to a well-diversified portfolio.
Biosyntech Fundamentals Growth
Biosyntech Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Biosyntech, and Biosyntech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biosyntech Pink Sheet performance.
| Return On Asset | -0.52 | |||
| Operating Margin | (33.33) % | |||
| Current Valuation | 116.44 K | |||
| Shares Outstanding | 116.44 M | |||
| Price To Earning | (0.01) X | |||
| Price To Sales | 0.0006 X | |||
| Revenue | 5.06 K | |||
| EBITDA | (6.32 M) | |||
| Cash And Equivalents | 1.44 M | |||
| Cash Per Share | 0.01 X | |||
| Book Value Per Share | (0.12) X | |||
| Cash Flow From Operations | (9.57 M) | |||
| Earnings Per Share | (0.1) X | |||
| Total Asset | 893.01 K | |||
| Retained Earnings | (18.04 M) | |||
| Current Asset | 692 K | |||
| Current Liabilities | 1.27 M | |||
About Biosyntech Performance
By evaluating Biosyntech's fundamental ratios, stakeholders can gain valuable insights into Biosyntech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Biosyntech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Biosyntech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
BioSyntech, Inc. develops biotherapeutic thermogels for tissue repair and therapeutic delivery. On May 12, 2010, Biosyntech Inc. filed for administration under the Bankruptcy and Insolvency Act. BIOSYNTECH INC is traded on PNK Exchange in the United States.Things to note about Biosyntech performance evaluation
Checking the ongoing alerts about Biosyntech for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Biosyntech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Biosyntech is not yet fully synchronised with the market data | |
| Biosyntech has some characteristics of a very speculative penny stock | |
| Biosyntech has a very high chance of going through financial distress in the upcoming years | |
| The company has a current ratio of 0.21, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Biosyntech until it has trouble settling it off, either with new capital or with free cash flow. So, Biosyntech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Biosyntech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Biosyntech to invest in growth at high rates of return. When we think about Biosyntech's use of debt, we should always consider it together with cash and equity. | |
| Biosyntech reported the previous year's revenue of 5.06 K. Net Loss for the year was (12.94 M) with profit before overhead, payroll, taxes, and interest of 24.8 K. | |
| Biosyntech currently holds about 1.44 M in cash with (9.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. |
- Analyzing Biosyntech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biosyntech's stock is overvalued or undervalued compared to its peers.
- Examining Biosyntech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biosyntech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biosyntech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Biosyntech's pink sheet. These opinions can provide insight into Biosyntech's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in Biosyntech Pink Sheet
If you are still planning to invest in Biosyntech check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biosyntech's history and understand the potential risks before investing.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |